Improving HPV vaccination in emergency departments for high-risk adults
Official title: Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized Adults Via the Emergency Department
Run by University of Alabama at Birmingham · NCT06229353 · Data updated 2026-05-14
This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.
This study tests a new way to give the HPV vaccine to adults aged 18 to 45 in emergency departments to see if it helps more people get vaccinated.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 45 Years |
| Sex | All |
| Enrollment | 610 (estimated) |
| Sponsor | University of Alabama at Birmingham Academic / other |
| Locations | 1 site (Birmingham, Alabama) |
| Trial ID | NCT06229353 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18-45 who have not received the HPV vaccine or have not completed the vaccine series.
✕Probably not a fit
Patients who are under 18 or over 45 years old, or those with known HPV infections or abnormal HPV test results, will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to evaluate the effectiveness of a novel approach to increase HPV vaccination coverage among adults aged 18 to 45 who are under-immunized. It will develop and pilot an HPV vaccination protocol specifically in the emergency department (ED) setting, targeting two age groups: 18-26 and 27-45 years old. The study will assess whether the ED can serve as a viable location for administering the Gardasil 9 vaccine to eligible patients who have not completed their vaccination series. The approach will be evaluated for its feasibility and impact on vaccination rates.
Why it matters
Potential benefit: If successful, this study could significantly increase HPV vaccination rates among high-risk adults, reducing the incidence of HPV-related diseases.
How similar studies have gone: Other studies have shown success in utilizing emergency department settings for vaccination programs, indicating potential for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * aged 18-45 years old * in good functional capacity, as determined by the ED-attending clinician * no known infection with HPV high risk strain types 6, 11, 16 and 18. Exclusion Criteria: * will not receive vaccine if participants lack mental clarity and if running a fever or in some pain. * Patients aged \<18 or \> 45 years of age. * Female patients with abnormal HPV results (including those with the high-risk HPV strain types 6, 11, 16, and 18) as determined by a previous PAP smear test or HPV test. * Female patients who are known to be pregnant. * Male patients with known cases of HPV-associated infections will also be excluded from the study
Where it's running
-
University of Alabama at Birmingham
Birmingham, Alabama, United States Recruiting
Study contacts
- Principal investigator: Andrzej Kulczycki, PhD — University of Alabama at Birmingham
- Study coordinator: Andrzej Kulczycki, PhD
- Email: andrzej@uab.edu
- Phone: 2059349875
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
HPV self-sampling in the ED to screen under-screened women
This study tests whether giving an HPV self-sampling kit in the emergency department can help under-screened women get screened for cervical cancer and find those with HPV to guide follow-up care.
-
CHW4CervixHealth: HPV self-collection kits with community health workers
This project will test whether giving self-collection HPV kits during community workshops led by community health workers helps increase screening among under-screened women aged 25–65 and will first compare kit results to clinical Pap smears.
-
Preventing cervical cancer with rapid HPV genotyping and same-day self-sampling
This project tests whether a rapid HPV genotyping test on self-collected and provider-collected samples can quickly identify women at high risk so they can receive same-day screening and treatment in low-resource settings.
-
Lidocaine injection before surgery for oropharyngeal cancer
This study tests if giving a lidocaine injection before surgery can help improve outcomes for patients with oropharyngeal cancer.
-
High resolution anal examination for HPV and anal cancer detection
This study is testing how well high-resolution anal exams can help find high-risk HPV and anal cancer in people who are more likely to have these issues.
-
Evaluating the Gardasil HPV vaccine's immune responses in people with and without HIV
This study is testing how well the Gardasil HPV vaccine works in people born male, both with and without HIV, to see how their immune systems respond to the vaccine.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.